https://www.europesays.com/1948031/ Tempest Reports Year End 2024 Financial Results and Provides Business Update #america #atezolizumab #bevacizumab #business #ClinicalTrial #FDA #UnitedStates #UnitedStatesOfAmerica #unresectable #US #USA
Recent searches
Search options
Administered by:
#Atezolizumab
0 posts0 participants0 posts today
#atezolizumab SmPC for Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1,200 mg concentrate for solution for infusion has been updated with changes to sections 2. Qualitative; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.1 List of excipients; 6.3 Shelf life; 6.6 Specia ...
#atezolizumab SmPC for Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1,200 mg concentrate for solution for infusion has been updated with changes to sections 2. Qualitative; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.1 List of excipients; 6.3 Shelf life; 6.6 Specia ...
#atezolizumab SmPC for Tecentriq 1,875 mg solution for injection has been updated with changes to sections 2. Qualitative; 3. Pharmaceutical form; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; Revised: 20 December 2024. 
https://www.medicines.org.uk/emc/product/15037/smpc Change log: htt ...
www.medicines.org.ukTecentriq 1,875 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)Tecentriq 1,875 mg solution for injection - Summary of Product Characteristics (SmPC) by Roche Products Limited
#atezolizumab SmPC for Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1,200 mg concentrate for solution for infusion has been updated with changes to sections 2. Qualitative; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.1 List of excipients; 6.3 Shelf life; 6.6 Specia ...
#atezolizumab SmPC for Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1,200 mg concentrate for solution for infusion has been updated with changes to sections 2. Qualitative; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.1 List of excipients; 6.3 Shelf life; 6.6 Specia ...
#atezolizumab SmPC for Tecentriq 1,875 mg solution for injection has been updated with changes to sections 2. Qualitative; 3. Pharmaceutical form; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; Revised: 20 December 2024. https://www.medicines.org.uk/emc/product/15037/smpc Change log: htt ...
www.medicines.org.ukTecentriq 1,875 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)Tecentriq 1,875 mg solution for injection - Summary of Product Characteristics (SmPC) by Roche Products Limited
#atezolizumab SmPC for Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1,200 mg concentrate for solution for infusion has been updated with changes to sections 2. Qualitative; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.1 List of excipients; 6.3 Shelf life; 6.6 Specia ...
#atezolizumab SmPC for Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1,200 mg concentrate for solution for infusion has been updated with changes to sections 2. Qualitative; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.1 List of excipients; 6.3 Shelf life; 6.6 Specia ...
#atezolizumab SmPC for Tecentriq 1,875 mg solution for injection has been updated with changes to sections 2. Qualitative; 3. Pharmaceutical form; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; Revised: 20 December 2024. https://www.medicines.org.uk/emc/product/15037/smpc Change log: htt ...
www.medicines.org.ukTecentriq 1,875 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)Tecentriq 1,875 mg solution for injection - Summary of Product Characteristics (SmPC) by Roche Products Limited
#atezolizumab SmPC for Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1,200 mg concentrate for solution for infusion has been updated with changes to sections 2. Qualitative; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.1 List of excipients; 6.3 Shelf life; 6.6 Specia ...
#atezolizumab SmPC for Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1,200 mg concentrate for solution for infusion has been updated with changes to sections 2. Qualitative; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.1 List of excipients; 6.3 Shelf life; 6.6 Specia ...
#atezolizumab SmPC for Tecentriq 1,875 mg solution for injection has been updated with changes to sections 2. Qualitative; 3. Pharmaceutical form; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; Revised: 20 December 2024. https://www.medicines.org.uk/emc/product/15037/smpc Change log: htt ...
www.medicines.org.ukTecentriq 1,875 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)Tecentriq 1,875 mg solution for injection - Summary of Product Characteristics (SmPC) by Roche Products Limited
#atezolizumab SmPC for Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1,200 mg concentrate for solution for infusion has been updated with changes to sections 2. Qualitative; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.1 List of excipients; 6.3 Shelf life; 6.6 Specia ...
#atezolizumab SmPC for Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1,200 mg concentrate for solution for infusion has been updated with changes to sections 2. Qualitative; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.1 List of excipients; 6.3 Shelf life; 6.6 Specia ...
#atezolizumab SmPC for Tecentriq 1,875 mg solution for injection has been updated with changes to sections 2. Qualitative; 3. Pharmaceutical form; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; Revised: 20 December 2024. https://www.medicines.org.uk/emc/product/15037/smpc Change log: htt ...
www.medicines.org.ukTecentriq 1,875 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)Tecentriq 1,875 mg solution for injection - Summary of Product Characteristics (SmPC) by Roche Products Limited
#atezolizumab SmPC for Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1,200 mg concentrate for solution for infusion has been updated with changes to sections 2. Qualitative; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.1 List of excipients; 6.3 Shelf life; 6.6 Specia ...
#atezolizumab SmPC for Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1,200 mg concentrate for solution for infusion has been updated with changes to sections 2. Qualitative; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.1 List of excipients; 6.3 Shelf life; 6.6 Specia ...
#atezolizumab SmPC for Tecentriq 1,875 mg solution for injection has been updated with changes to sections 2. Qualitative; 3. Pharmaceutical form; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; Revised: 20 December 2024. https://www.medicines.org.uk/emc/product/15037/smpc Change log: htt ...
www.medicines.org.ukTecentriq 1,875 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)Tecentriq 1,875 mg solution for injection - Summary of Product Characteristics (SmPC) by Roche Products Limited
#atezolizumab SmPC for Tecentriq 840 mg concentrate for solution for infusion Tecentriq 1,200 mg concentrate for solution for infusion has been updated with changes to sections 2. Qualitative; 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.1 List of excipients; 6.3 Shelf life; 6.6 Specia ...